First-choice drug for newly diagnosed epilepsy

Lancet

Volumn 369, Issue 9566, 2007, Pages 970-971

  French, Jacqueline A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADJUVANT THERAPY; ADULT; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CLINICAL PRACTICE; COGNITIVE DEFECT; CONTROLLED RELEASE FORMULATION; DRUG CHOICE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULARY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FETUS MALFORMATION; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; INFANT; INFANTILE SPASM; INSOMNIA; LENNOX GASTAUT SYNDROME; LIVER FAILURE; LIVER FUNCTION TEST; MONOTHERAPY; PANCREATITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; THROMBOCYTE COUNT; TONIC CLONIC SEIZURE; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT GAIN;

ADULT; ANTICONVULSANTS; CHILD; EPILEPSY; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33947273533     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60470-X     Document Type: Note

References (14)

1. Marson A., Al-Kharusi A., Alwaidh M., and on behalf of the SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1000-1015
2. Marson A., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1016-1026
3. National Institute for Clinical Excellence. Newer drugs for epilepsy in adults (March, 2004). http://www.nice.org.uk/TA076guidance (accessed May 4, 2004).
4. French J., and Chadwick D. Drugs for the elderly: using the old to focus on the new. Neurology 64 (2005) 1834-1835
5. Arroyo S., and Sander J. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Neurology 53 (1999) 1170-1174
6. Glauser T., Ben-Menachem E., Bourgeois B., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47 (2006) 1094-1120
7. Chapman S., Wacksman G., and Patterson B. Pancreatitis associated with valproic acid: a review of the literature. Pharmacotherapy 21 (2001) 1549-1560
8. Konig S., Siemes H., Blaker F., et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 35 (1994) 1005-1015
9. Tennis P., and Stern R. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 49 (1997) 542-546
10. Wong I., Mawer G., and Sander J. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 33 (1999) 1037-1042
11. Ben-Menachem E., Brodie M., Perucca E., and on behalf of the N01061 Study Group. Efficacy of levetiracetam monotherapy; randomized double-blind head-to-head comparison with carbamazepine-CR in newly diagnosed epilepsy patients with partial onset or generalised tonic-clonic seizures (April 4, 2006), American Academy of Neurology, San Diego, California
12. Sadler M. Lamotrigine associated with insomnia. Epilepsia 40 (1999) 322-325
13. Pennell P., Newport D., Stowe Z., Helmers S., Montgomery J., and Henry T. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62 (2004) 292-295
14. Meador K., Baker G., Finnell R., and for the NEAD Study Group. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 67 (2006) 407-412